Littérature scientifique sur le sujet « Oligonucleotidi antisenso »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Oligonucleotidi antisenso ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Oligonucleotidi antisenso"
Goddard, Layla R., Charlotte E. Mardle, Hassan Gneid, Ciara G. Ball, Darren M. Gowers, Helen S. Atkins, Louise E. Butt, Jonathan K. Watts, Helen A. Vincent et Anastasia J. Callaghan. « An Investigation into the Potential of Targeting Escherichia coli rne mRNA with Locked Nucleic Acid (LNA) Gapmers as an Antibacterial Strategy ». Molecules 26, no 11 (4 juin 2021) : 3414. http://dx.doi.org/10.3390/molecules26113414.
Texte intégralBožič, Tim, Matja Zalar, Boris Rogelj, Janez Plavec et Primož Šket. « Structural Diversity of Sense and Antisense RNA Hexanucleotide Repeats Associated with ALS and FTLD ». Molecules 25, no 3 (25 janvier 2020) : 525. http://dx.doi.org/10.3390/molecules25030525.
Texte intégralDung, Tran Huu, Seung-Rok Lee, Suhk-Dong Han, Seon-Jeong Kim, Yeon-Mi Ju, Myong-Soo Kim et Hoon Yoo. « Chitosan-TPP Nanoparticle as a Release System of Antisense Oligonucleotide in the Oral Environment ». Journal of Nanoscience and Nanotechnology 7, no 11 (1 novembre 2007) : 3695–99. http://dx.doi.org/10.1166/jnn.2007.041.
Texte intégralCHAKRABORTY, Rila, Dalia DASGUPTA, Samit ADHYA et Mukul K. BASU. « Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania ». Biochemical Journal 340, no 2 (25 mai 1999) : 393–96. http://dx.doi.org/10.1042/bj3400393.
Texte intégralZhao, Q., X. Song, T. Waldschmidt, E. Fisher et AM Krieg. « Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation ». Blood 88, no 5 (1 septembre 1996) : 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.1788.
Texte intégralZhao, Q., X. Song, T. Waldschmidt, E. Fisher et AM Krieg. « Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation ». Blood 88, no 5 (1 septembre 1996) : 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.bloodjournal8851788.
Texte intégralStudzińska, Sylwia, Ewelina Zawadzka, Szymon Bocian et Michał Szumski. « Synthesis and application of stationary phase for DNA-affinity chromatographic analysis of unmodified and antisense oligonucleotide ». Analytical and Bioanalytical Chemistry 413, no 20 (24 juin 2021) : 5109–19. http://dx.doi.org/10.1007/s00216-021-03473-7.
Texte intégralPandiri, Kavya, Mohammed Abdul Samad, Nadeem Abbas Gulamus et Hajera Khanam. « Medicinal Applications of Antisense Oligonucleotides : A Review ». INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH 5, no 02 (1 avril 2020) : 30–36. http://dx.doi.org/10.21477/ijapsr.5.2.2.
Texte intégralYamamoto, T., R. P. Moerschell, L. P. Wakem, S. Komar-Panicucci et F. Sherman. « Strand-specificity in the transformation of yeast with synthetic oligonucleotides. » Genetics 131, no 4 (1 août 1992) : 811–19. http://dx.doi.org/10.1093/genetics/131.4.811.
Texte intégralTanaka, T., C. C. Chu et W. E. Paul. « An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. » Journal of Experimental Medicine 175, no 2 (1 février 1992) : 597–607. http://dx.doi.org/10.1084/jem.175.2.597.
Texte intégralThèses sur le sujet "Oligonucleotidi antisenso"
Lombardini, Lorenza <1982>. « Valutazione preclinica di oligonucleotidi antisenso come nuovo approccio terapeutico specifico per le leucemie acute con riarrangiamenti di MLL ». Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3238/1/Lombardini_Lorenza_Tesi.pdf.
Texte intégralChromosomal translocations involving 11q23/MLL gene represent frequent abnormalities in Acute Myeloid Leukemias (AML) subtype FAB M5 and M4, Acute Lymphoblastic Leukemias (ALL) and Biphenotypic Leukemias. MLL-related leukemias are generally associated with aggressive disease and poor prognosis. MLL-related leukemias need validation of new therapies, so we designed and validated anti-MLL siRNA to downregulate MLL-fusion oncogenes. We tested anti-MLL siRNA in MLL-carrying acute leukemias cell lines, and we evaluated both MLL mRNA downregulation, cellular viability and proliferation, and protein inhibition. We also evaluated gene expression of MLL-dependent genes. We generated bioluminescent acute leukemias xenograft mouse models of the most frequent MLL fusion genes. We evaluated leukemias trafficking and progression, and we evaluated delivery methods for siRNA delivery in vivo.
Lombardini, Lorenza <1982>. « Valutazione preclinica di oligonucleotidi antisenso come nuovo approccio terapeutico specifico per le leucemie acute con riarrangiamenti di MLL ». Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3238/.
Texte intégralChromosomal translocations involving 11q23/MLL gene represent frequent abnormalities in Acute Myeloid Leukemias (AML) subtype FAB M5 and M4, Acute Lymphoblastic Leukemias (ALL) and Biphenotypic Leukemias. MLL-related leukemias are generally associated with aggressive disease and poor prognosis. MLL-related leukemias need validation of new therapies, so we designed and validated anti-MLL siRNA to downregulate MLL-fusion oncogenes. We tested anti-MLL siRNA in MLL-carrying acute leukemias cell lines, and we evaluated both MLL mRNA downregulation, cellular viability and proliferation, and protein inhibition. We also evaluated gene expression of MLL-dependent genes. We generated bioluminescent acute leukemias xenograft mouse models of the most frequent MLL fusion genes. We evaluated leukemias trafficking and progression, and we evaluated delivery methods for siRNA delivery in vivo.
Albouz, Soulaf. « Evaluation de l’efficacité de l’atovaquone encapsulée associée à des oligonucléotides antisens anti-ARNm de topoisomérase II chez Plasmodium falciparum ». Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS079.
Texte intégralAccording to the estimations of theWHO, in 2015, 212million cases ofmalariahave been reported(WHO,2016). These figuresmakemalariathe most deadlyparasitic diseasein the world, with429.000deaths per year. Some treatments against Plasmodium falciparum exist. However, no really good treatment option can be found in monotherapy due to the resistance emergency. Therefore To reduce the risk of resistance, WHO has recommended since 2001 combination therapies, which is basically an Artemisinin Combined Therapy (ACT), as first-line treatment. The main problem of commercialized bi-therapy is that they are composed of two molecules with individual resistance which leaded to the emergence of resistance to the latest ACTs such as a dihydroartemisinin /piperaquine combinationmainly in South-East Asia.Thus the use of new therapeutic combination strategy that can bypass the parasites' mechanisms of resistance is urgent to effectively treat malaria. As the pathway from drug discovery to drug commercialization is both long and very expensive, it is essential to develop ways to improve existing antimalarial treatments. In the first place it’s necessary to find a new antimalarial formulation based on an already commercialized drug to modify its biodisponibility and its mechanism of action in order to revert the resistance. In the second place its necessary to associate this formulation with a novel none commercialized antimalarial strategy such as the antisens oligonucleotides already usedinhumanhealth. In our lab we have developed nanoemulsions containing atovaquone and antisense oligonucleotides anti topoisomerase II against P. falciparum.Nanoemulsionsvectoringantisens oligonucleotidesandused againstP. falciparum topoisomerase II(NE/AST) showed encouraging anti-parasite killing results.Additionalresultshave showna synergistic in vitro effectwithantimalarial drugs(chloroquine, dihydroartemisinin and atovaquone) in sensitive and resistances strains. Moreover NE/ASTrestricted Topoisomerase II gene expression and blocked the cell cycle in G2/M phase leading to parasite’s death by mitophagy.As Drug delivery systemscan improve the efficacy ofcommon antimalarial drugs by delivering the drug to its target, while protecting it from degradation in biological environment and increasing its biodisponibility, our nanoemulsions containing atovaquone (ATQ) leaded to reversion of atovaquone resistance with 5 fold decrease in its IC50. Observations made with confocal microscopy have shown mitochondrial alteration after ATQ treatment.Our novel and original bi-therapy is focused on the association ofATQ with NE/AST (ATQ/AST).We obtained an IC50 8-fold lower than atovaquone’s IC50with total inhibition of parasites’ capacity to reinfect new red blood cells. A cytoadherence test of parasitized erythrocytes to endothelial cells revealed a strong capacity of cytoadherence inhibition of ATQ / AST, a promising result in the treatment of cerebral malaria
Yannopoulos, Constantin G. « Synthesis and targeting of antisense oligonucleotides ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0014/NQ37032.pdf.
Texte intégralLin, Zhaoru. « Characterisation of antisense oligonucleotide-stimulated ribosomal frameshifting ». Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609380.
Texte intégralGODARD, GERARD. « Oligonucleotides antisens modifies : potentialites et limites ». Paris 6, 1994. http://www.theses.fr/1994PA066374.
Texte intégralRouleau, Samuel. « Oligonucléotides comme modulateurs de l'expression génique ». Thèse, Université de Sherbrooke, 2017. http://hdl.handle.net/11143/11570.
Texte intégralAbstract : RNA is a versatile biological molecule. Like DNA, it can contain and transmit genetic information. Like proteins, it can accomplish multiple biological functions. Also, its most known role remains that of intermediary between DNA and proteins. RNA is thus a key player in many biological processes. This gives it an immense therapeutic potential which remains largely untapped. To fulfill its functions, RNA must adopt a precise threedimensional structure that is dependent on both its sequence and its environment. Thus, by modifying the structure of an RNA, it is possible to modulate its function. This is the overall objective of the work presented in this thesis. To achieve this, small antisense oligonucleotides (ASO) have been used. This strategy has several advantages. As ASO bind their target with Watson-Crick base pairs, they offer great specificity and their design is easy. Moreover, reliance on structural data and RNA structure prediction softwares makes it easy to identify the regions to be targeted with ASO. Finally, this technique is versatile since it is possible to target different RNA motifs. The first target was the HDV self-cleaving motif. This RNA, which catalyzes a self-cleaving reaction, has been modified so that its activity became dependent on the binding of ASO. Several modules were thus created and combined in order to obtain ribozymes which responded to the presence of one or more ASO. By inserting these molecular switches into an mRNA’s UTR, the expression of this gene was modulated with the ASO. This has interesting applications for the regulation of genes in synthetic biology. Another target motif was the G-quadruplex (G4). This non-canonical structure exerts many biological functions and therefore represents an interesting therapeutic target. When present in the mRNA’s 5’UTR, G4 generally lead to a decrease in translation. Using ASO that prevent G4 formation, we were able to increase the translation of the target gene. In addition, it has been possible to develop ASO which promote the formation of a G4 in order to decrease the expression of the target. Finally, in the last chapter of this thesis, it is demonstrated that the G4 present in the primary microRNAs influence their maturation in mature microRNAs. ASO targeting these G4 have been used in order to promote the maturation of tumor suppressor microRNAs, which has an interesting therapeutic potential. The work presented in this thesis clearly demonstrates that ASO are ideal for targeting and altering the structure of specific RNA motifs.
Chalk, Alistair. « Computational prediction of antisense oligonucleotides and siRNAs / ». Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-376-0/.
Texte intégralGill, Taylor Elizabeth. « Selective targeting of MYC by antisense oligonucleotides ». Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/115602.
Texte intégralThis electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.
Cataloged from student-submitted PDF version of thesis.
Includes bibliographical references (pages 181-208).
MYC is one of the most commonly dysregulated genes across all cancers. As a master transcription factor with greater than 10,000 binding sites throughout the genome, the MYC oncoprotein coordinates a transcriptional regulatory network consisting of approximately 15% of all genes, controlling cancer hallmark expression programs responsible for cellular proliferation, growth, metabolism, and evasion from apoptosis. MYC dysregulation occurs genetically, epigenetically, and post-transcriptionally through a wide variety of mechanisms. Despite its well-characterized properties as a proto-oncogene, direct potent and selective inhibition of MYC remains a significant challenge. Models of systemic MYC inhibition utilizing inducible genetic constructs in mice have revealed that inhibition of MYC activity leads to potent tumor regression with an evident therapeutic window, suggesting that pharmacologic MYC inhibition may be a viable cancer therapeutic strategy. Small molecule inhibitors designed to block MYC protein activity exhibit low potency, display poor selectivity, and lack antitumor efficacy, which has led MYC to be historically classified as 'undruggable.' Efforts aimed at indirectly targeting MYC transcription often lead to development of resistance characterized by reinforced expression of MYC. Clearly, alternate strategies are needed to achieve selective and potent inhibition of MYC. The goals of this research were to develop antisense oligonucleotides specifically targeted against the MYC mRNA to achieve potent inhibition of MYC translation, and to characterize the activity of these molecules as specific modulators of MYC expression and as prototypical MYC-directed therapeutics. We designed and synthesized a library of MYC-targeting antisense oligonucleotides (MYCASOs) containing several chemical synthetic features to increase target affinity and stability. Treatment of MYC-expressing cancer cells with MYCASOs leads to RNase H-mediated cleavage of MYC mRNA and a potent decrease in MYC protein levels. MYC knockdown is accompanied by significant effects on cellular viability and inhibition of cellular proliferation. Furthermore, MYCASO treatment specifically perturbs MYC-driven gene expression signatures. In a MYC-induced murine model of hepatocellular carcinoma, MYCASO treatment leads to cleavage of the MYC transcript, decreased MYC protein levels within tumors, and reduced tumor burden. MYCASOs represent a new chemical tool for in vitro and in vivo modulation of MYC activity, and promising therapeutic agents for MYC-addicted tumors.
by Taylor Elizabeth Gill.
Ph. D. in Biomedical Engineering
Åström, Hans. « Studies on phosphate ester cleavage and development of oligonucleotide based artificial nucleases (OBAN's) / ». Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-935-8/.
Texte intégralLivres sur le sujet "Oligonucleotidi antisenso"
A, Stein Cy, et Krieg Arthur M, dir. Applied antisense oligonucleotide technology. New York : Wiley-Liss, 1998.
Trouver le texte intégral1956-, Sanghvi Yogesh S., Cook P. Dan 1944-, American Chemical Society. Division of Carbohydrate Chemistry. et American Chemical Society Meeting, dir. Carbohydrate modifications in antisense research. Washington, DC : American Chemical Society, 1994.
Trouver le texte intégralSaghir, Akhtar, dir. Delivery strategies for antisense oligonucleotide therapeutics. Boca Raton : CRC Press, 1995.
Trouver le texte intégralThomas, Tuschl, Rossi John J et New York Academy of Sciences, dir. Oligonucleotide therapeutics. Boston, Mass : Blackwell on behalf of the New York Academy of Sciences, 2006.
Trouver le texte intégralJ, Rossi John, Gait, M. J. (Michael J.), Eckstein Fritz 1932- et New York Academy of Sciences, dir. Oligonucleotide therapeutics : Fourth annual meeting. Boston, Mass : Published by Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.
Trouver le texte intégralSudhir, Agrawal, dir. Antisense therapeutics. Totowa, N.J : Humana Press, 1996.
Trouver le texte intégralUgent, Steven Jay. Antisense oligonucleotides : Psoralen photoreactivity and enzymatic resistance. [S.l : s.n.], 1991.
Trouver le texte intégralCrooke, Stanley T. Therapeutic applications of oligonucleotides. New York : Springer-Verlag, 1995.
Trouver le texte intégralIan, Phillips M., dir. Antisense therapeutics. 2e éd. Totowa, N.J : Humana Press, 2005.
Trouver le texte intégralIan, Phillips M., dir. Antisense therapeutics. 2e éd. Totowa, N.J : Humana Press, 2005.
Trouver le texte intégralChapitres de livres sur le sujet "Oligonucleotidi antisenso"
Bremer, Jeroen, et Peter C. van den Akker. « In Vivo Models for the Evaluation of Antisense Oligonucleotides in Skin ». Dans Methods in Molecular Biology, 315–20. New York, NY : Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2010-6_21.
Texte intégralScherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, Marc N. Potenza, Tayfun Uzbay, Lisiane Bizarro, David C. S. Roberts et al. « Antisense Oligonucleotides ». Dans Encyclopedia of Psychopharmacology, 122–27. Berlin, Heidelberg : Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_384.
Texte intégralNeumann, Inga D., et Peter J. Flor. « Antisense Oligonucleotides ». Dans Encyclopedia of Psychopharmacology, 162–67. Berlin, Heidelberg : Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_384.
Texte intégralCrooke, Stanley T. « Antisense Oligonucleotides ». Dans Cancer Therapeutics, 299–336. Totowa, NJ : Humana Press, 1997. http://dx.doi.org/10.1007/978-1-59259-717-8_15.
Texte intégralShah, Neel Jayesh. « Antisense Oligonucleotides ». Dans Introduction to Basics of Pharmacology and Toxicology, 407–11. Singapore : Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9779-1_33.
Texte intégralNeumann, Inga D., et Peter J. Flor. « Antisense Oligonucleotides ». Dans Encyclopedia of Psychopharmacology, 1–7. Berlin, Heidelberg : Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-27772-6_384-2.
Texte intégralLópez-Martínez, Andrea, Patricia Soblechero-Martín et Virginia Arechavala-Gomeza. « Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy ». Dans Methods in Molecular Biology, 217–33. New York, NY : Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2010-6_14.
Texte intégralNyce, Jonathan W. « Respirable Antisense Oligonucleotides ». Dans New Drugs for Asthma, Allergy and COPD, 361–64. Basel : KARGER, 2001. http://dx.doi.org/10.1159/000062198.
Texte intégralZhou, Haiyan. « Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion ». Dans Methods in Molecular Biology, 53–62. New York, NY : Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2010-6_3.
Texte intégralKrieg, A. M. « Immune Stimulation by Oligonucleotides ». Dans Antisense Research and Application, 243–62. Berlin, Heidelberg : Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-58785-6_8.
Texte intégralActes de conférences sur le sujet "Oligonucleotidi antisenso"
Brown, Paige K., Ammar T. Qureshi, Daniel J. Hayes et W. Todd Monroe. « Targeted Gene Silencing With Light and a Silver Nanoparticle Antisense Delivery System ». Dans ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53647.
Texte intégralPuzanova, E. V. « Prospects for the use of unmodified antisense oligonucleotides in the regulation of the synthesis of secondary metabolites of essential oil plants ». Dans 2nd International Scientific Conference "Plants and Microbes : the Future of Biotechnology". PLAMIC2020 Organizing committee, 2020. http://dx.doi.org/10.28983/plamic2020.202.
Texte intégralThomas, Sufi M., et Danith Ly. « Abstract 3301 : Guanidinium antisense oligonucleotides for cancer therapy. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3301.
Texte intégralVan Aerschot, Arthur, Mark Vandermeeren, Johan Geysen, Walter Luyten, Marc Miller, David Atkins, Sonia Preveral, Ester Saison-Behmoaras et Piet Herdewijn. « In vitro evaluation of hexitol nucleic acid antisense oligonucleotides ». Dans XIth Symposium on Chemistry of Nucleic Acid Components. Prague : Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 1999. http://dx.doi.org/10.1135/css199902151.
Texte intégralZheng, Shi-ying, Dong Jiang, Jin-feng Ge et Zhen-ya Shen. « T Cell Apoptosis Was Inhibited by Fas of Antisense Oligonucleotide ». Dans 2010 4th International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2010. http://dx.doi.org/10.1109/icbbe.2010.5516974.
Texte intégralZhang, M., J. R. Crosby, D. Bai, C. Zhao, A. R. Macleod et S. Guo. « Antisense Oligonucleotide Mediated Reduction of TG2 Attenuates Pulmonary Fibrosis in Mice ». Dans American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7438.
Texte intégralKuijper, Elsa, Maurice Overzier, Ernst Suidgeest, Louise van der Weerd, Lodewijk Toonen et Willeke van Roon-Mom. « I02 Therapeutic effect of antisense oligonucleotide treatment in YAC128 Huntington mice ». Dans EHDN 2022 Plenary Meeting, Bologna, Italy, Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jnnp-2022-ehdn.228.
Texte intégralRipple, Michael J., Dahui You, Joseph Giamo, Andrew Sewell, David M. Becnel et Stephania A. Cormier. « Inhaled IL-4 Receptor A Antisense Oligonucleotide Prevents RSV-Mediated Asthma ». Dans American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6185.
Texte intégralLogan, Andrew E., Timothy R. Wilson, Patrick G. Johnston et Daniel B. Longley. « Abstract C12 : Preclinical characterization of a novel FLIP‐targeted antisense phosphorothioate oligonucleotide ». Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009 ; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-c12.
Texte intégralSakurai, Kazuo, Shinichi Mochizuki et Jusaku Minari. « Antisense Oligonucleotides Delivery to the Antigen Presenting Cells by using Schizophyllan ». Dans 2008 MRS Fall Meetin. Materials Research Society, 2008. http://dx.doi.org/10.1557/proc-1140-hh05-17.
Texte intégralRapports d'organisations sur le sujet "Oligonucleotidi antisenso"
Liu, Yong-Yu. Antisense Oligonucleotides to Glucosylceramide Synthase Can Reverse Multidrug Resistance in Breast Cancer. Fort Belvoir, VA : Defense Technical Information Center, juin 2002. http://dx.doi.org/10.21236/ada407440.
Texte intégralChakraborty, Srijani. The Dawn of RNA Therapeutics. Spring Library, décembre 2020. http://dx.doi.org/10.47496/sl.blog.19.
Texte intégral